PLA2G2A and psoriasis: In agreement, NP was associated with upregulation of several HDPs such as lysozyme (LYZ), peptidase inhibitor 3 (PI3), secretory phospholipase A2 (sPLA2; PLA2G2A), myeloid cathelicidin 3 (ECATH3), granulysin (GNLY), secretory leukocyte peptidase inhibitor (SLPI), acid phosphatase 5, tartrate resistant (ACP5), and psoriasis (S100A7).